Clinical Trial: A Single-center, Phase II Clinical Study of Sacituzumab Govitecan Combined With Toripalimab as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLC

U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07438600) titled 'A Single-center, Phase II Clinical Study of Sacituzumab Govitecan Combined With Toripalimab as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLC' on Feb. 22.

Brief Summary: This is a prospective, open, single-center, single-arm phase II clinical study in non-small cell lung cancer (NSCLC) without common EGFR-sensitive mutations (Ex19del and L858R) or ALK fusion variants identified in the central laboratory. To evaluate the efficacy and safety of neoadjuvant therapy of sacituzumab govitecan combined with toripalimab.

Study Start Date: Feb. 24

Study Type: INTERVENTIONAL

Condition: NSCLC (Non-small Cell Lung Cancer)

Intervent...